SMMT
Summit Therapeutics Inc.
Biotechnology
Market Cap$13.84B
5Y Perf.+398.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SMMT vs TNGX
Revenue, margins, valuation, and 5-year total return — side by side.
TNGX
Tango Therapeutics, Inc.
Biotechnology
Market Cap$3.21B
5Y Perf.+126.6%
SMMT vs TNGX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SMMT | TNGX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $13.84B | $3.21B |
| Revenue (TTM) | $0.00 | $62M |
| Net Income (TTM) | $-1.21B | $-102M |
| Gross Margin | — | 97.3% |
| Operating Margin | — | -178.4% |
| Total Debt | $21M | $34M |
| Cash & Equiv. | $225M | $112M |
SMMT vs TNGX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SMMT
TNGX
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Summit Therapeutics… (SMMT) | 100 | 498.5 | +398.5% |
| Tango Therapeutics,… (TNGX) | 100 | 226.6 | +126.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SMMT vs TNGX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TNGX leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SMMT
Summit Therapeutics Inc.
The Specific-Use Pick
In this particular matchup, SMMT is outpaced on most metrics by others in the set.
Best for: healthcare exposure
TNGX
Tango Therapeutics, Inc.
The Income Pick
TNGX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.81
- Rev growth 48.3%, EPS growth 26.9%, 3Y rev CAGR 35.9%
- 130.9% 10Y total return vs SMMT's 108.3%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TNGX | 48.3% revenue growth vs SMMT's -402.6% |
| Stability / Safety | TNGX | Beta 1.81 vs SMMT's 1.89 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TNGX | +17.7% vs SMMT's -26.2% |
| Efficiency (ROA) | TNGX | -36.3% ROA vs SMMT's -243.1%, ROIC -38.5% vs -220.2% |
SMMT vs TNGX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2025
SMMT vs TNGX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTNGXLAGGINGSMMT
SMMTSummit Therapeutics I…
0leads
TNGXTango Therapeutics, I…
4leads
6 Total Categories
CATEGORYLEADERvs SMMTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TNGX1/1
Valuation MetricsMultiples, price ratios, and targets
TNGX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TNGX5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
TNGX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TNGX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TNGX and SMMT operate at a comparable scale, with $62M and $0 in trailing revenue.
| Metric | SMMTSummit Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $62M |
| EBITDAEarnings before interest/tax | -$1.0B | -$109M |
| Net IncomeAfter-tax profit | -$1.2B | -$102M |
| Free Cash FlowCash after capex | -$385M | -$140M |
| Gross MarginGross profit ÷ Revenue | — | +97.3% |
| Operating MarginEBIT ÷ Revenue | — | -178.4% |
| Net MarginNet income ÷ Revenue | — | -162.9% |
| FCF MarginFCF ÷ Revenue | — | -2.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -166.7% | +11.8% |
TNGX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
TNGX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SMMTSummit Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| Market CapShares × price | $13.8B | $3.2B |
| Enterprise ValueMkt cap + debt − cash | $13.6B | $3.1B |
| Trailing P/EPrice ÷ TTM EPS | -12.40x | -27.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 51.47x |
| Price / BookPrice ÷ Book value/share | 20.26x | 7.93x |
| Price / FCFMarket cap ÷ FCF | — | — |
TNGX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
TNGX leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TNGX delivers a -50.3% return on equity — every $100 of shareholder capital generates $-50 in annual profit, vs $-3 for SMMT. SMMT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to TNGX's 0.10x. On the Piotroski fundamental quality scale (0–9), TNGX scores 4/9 vs SMMT's 1/9, reflecting mixed financial health.
| Metric | SMMTSummit Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -2.9% | -50.3% |
| ROA (TTM)Return on assets | -2.4% | -36.3% |
| ROICReturn on invested capital | -2.2% | -38.5% |
| ROCEReturn on capital employed | -2.0% | -34.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.10x |
| Net DebtTotal debt minus cash | -$204M | -$79M |
| Cash & Equiv.Liquid assets | $225M | $112M |
| Total DebtShort + long-term debt | $21M | $34M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
TNGX leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SMMT and TNGX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SMMT five years ago would be worth $30,000 today (with dividends reinvested), compared to $20,539 for TNGX. Over the past 12 months, TNGX leads with a +1774.6% total return vs SMMT's -26.2%. The 3-year compound annual growth rate (CAGR) favors SMMT at 109.5% vs TNGX's 90.1% — a key indicator of consistent wealth creation.
| Metric | SMMTSummit Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | +1.9% | +164.5% |
| 1-Year ReturnPast 12 months | -26.2% | +1774.6% |
| 3-Year ReturnCumulative with dividends | +820.1% | +586.6% |
| 5-Year ReturnCumulative with dividends | +200.0% | +105.4% |
| 10-Year ReturnCumulative with dividends | +108.3% | +130.9% |
| CAGR (3Y)Annualised 3-year return | +109.5% | +90.1% |
Evenly matched — SMMT and TNGX each lead in 3 of 6 comparable metrics.
Risk & Volatility
TNGX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TNGX is the less volatile stock with a 1.81 beta — it tends to amplify market swings less than SMMT's 1.89 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TNGX currently trades 83.1% from its 52-week high vs SMMT's 57.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SMMTSummit Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.89x | 1.81x |
| 52-Week HighHighest price in past year | $30.98 | $28.41 |
| 52-Week LowLowest price in past year | $13.83 | $1.03 |
| % of 52W HighCurrent price vs 52-week peak | +57.6% | +83.1% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 55.8 |
| Avg Volume (50D)Average daily shares traded | 3.5M | 3.4M |
TNGX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SMMT as "Buy" and TNGX as "Buy". Consensus price targets imply 19.5% upside for SMMT (target: $21) vs -3.7% for TNGX (target: $23).
| Metric | SMMTSummit Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.33 | $22.75 |
| # AnalystsCovering analysts | 20 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TNGX leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallTango Therapeutics, Inc. (TNGX)Leads 4 of 6 categories
Loading custom metrics...
SMMT vs TNGX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SMMT or TNGX a better buy right now?
Analysts rate Summit Therapeutics Inc.
(SMMT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SMMT or TNGX?
Over the past 5 years, Summit Therapeutics Inc.
(SMMT) delivered a total return of +200. 0%, compared to +105. 4% for Tango Therapeutics, Inc. (TNGX). Over 10 years, the gap is even starker: TNGX returned +129. 5% versus SMMT's +91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SMMT or TNGX?
By beta (market sensitivity over 5 years), Tango Therapeutics, Inc.
(TNGX) is the lower-risk stock at 1. 81β versus Summit Therapeutics Inc. 's 1. 89β — meaning SMMT is approximately 4% more volatile than TNGX relative to the S&P 500. On balance sheet safety, Summit Therapeutics Inc. (SMMT) carries a lower debt/equity ratio of 3% versus 10% for Tango Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SMMT or TNGX?
On earnings-per-share growth, the picture is similar: Tango Therapeutics, Inc.
grew EPS 26. 9% year-over-year, compared to -364. 5% for Summit Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SMMT or TNGX?
Summit Therapeutics Inc.
(SMMT) is the more profitable company, earning 0. 0% net margin versus -162. 9% for Tango Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMMT leads at 0. 0% versus -178. 4% for TNGX. At the gross margin level — before operating expenses — TNGX leads at 96. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SMMT or TNGX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SMMT or TNGX better for a retirement portfolio?
For long-horizon retirement investors, Tango Therapeutics, Inc.
(TNGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+129. 5% 10Y return). Summit Therapeutics Inc. (SMMT) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TNGX: +129. 5%, SMMT: +91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SMMT and TNGX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SMMT is a mid-cap quality compounder stock; TNGX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.